Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 83-88

  Orrell, Catherine ^a   Harling, Guy ^a   Lawn, Stephen D ^a,b   Kaplan, Richard ^c   McNally, Matthew ^c   Bekker, Linda Gail ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Department of Health   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE PLUS LAMIVUDINE PLUS NEVIRAPINE; DIDANOSINE PLUS LOPINAVIR PLUS RITONAVIR PLUS ZIDOVUDINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BRAIN TOXICITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COMMUNITY HEALTH SERVICES; COUNSELING; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RNA, VIRAL; SOUTH AFRICA; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33847353726     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Egeer M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
2. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 count and viral load change after initiating triple drug therapy. JAMA 2001; 286:2568-2577.
3. Laurent C, Gueye NFN, Ndour CT, et al. Long term benefits of highly active antiretroviral therapy in Senegalese HIV-1 infected adults. J Acquir Immune Defic Syndr 2005; 38:14-17.
4. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral therapy in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
5. Kumarasamy N, Solomon S, Chaguturu SK, et al. The safety tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in South India. AIDS 2003; 17:2267-2269.
6. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005; 353:2325-2334.
7. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large scale HIV treatment initiatives in sub-Saharan Africa: experience from Western Kenya. AIDS 2006; 20:41-48.
8. Tassie JM, Szumilin E, Calmy A, Goemaere E. Highly active antiretroviral therapy in resource poor settings: the experience of Médecins Sans Frontières. AIDS 2003, 17:1995-1997.
9. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003; 17(Suppl 3):S5-S15.
10. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224.
11. Bekker L-G, Myer L, Orrell C, Lawn SD, Wood R. Rapid scale up of community-based HIV treatment service: programme performances over 3 consecutive years in Guglethu, South Africa. S Afr Med J 2006; 96:315-320.
12. South African National Antiretroviral Treatment Guidelines, National Department of Health, South Africa. First edition, 2004 [cited 2007 Jan 25]. Available from: http://www.doh.gov.za/docs/factsheets/guidelines/ artguidelines04/intro.pdf
13. World Health Organisation. Scaling Up Antiretroviral Therapy in Resource Limited Settings - Guidelines for a Public Health Approach. Geneva: WHO; 2002.
14. Mandalia S, Parmar D, Fisher M, et al. Naively changing HAART. HIV Med 2002; 3:254-262.
15. Sabin C, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: a multicentre cohort study. BMJ 2005; 330:695-699.
16. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among patients accessing a community-based antiretroviral programme in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
17. Lawn SD, Myer L, Harling G, Orrell C, Bekker L-G, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776.
18. Antiretroviral Treatment Protocol. Provincial Administration of the Western Cape, South Africa. 2nd Edition, 2004 [cited 2006 August 9]. Available from: http://www.epi.uct.ac.za/artrollout/
19. Martinez E. The reassurance of experience. Int J STD AIDS 2003; 14(Suppl 1):20-28.
20. Masquelier B, Pereira E, Peytavin G, et al. Intermittent viraemia during first line, protease inhibitor containing therapy: significance and relationship with drug resistance. J Clin Virol 2005; 33:75-78.
21. Røge BT, Barfod TS, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomised study. HIV Med 2004; 5:344-351.
22. Nettles N, Kieffer T, Kwon P, et al. Intermittent HIV-1 viraemia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817-829.
23. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 1003; 17:1741-1751.
24. Orrell C, Badri M, Wood R. Measuring adherence in a community setting: which measure most valuable? 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract WePEB57.
25. Weidle P, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patient's response, survival and drug resistance. Lancet 2002; 360:34-40.
26. Oosterhout J, Bodasing N, Kumwenda J, et al. Evaluation of antiretroviral therapy results in a resource setting in Blantyre, Malawi. Trop Med Int Health 2005; 10:464-470.
27. Colebunders R, Moses KR, Laurence J, et al. A new model to monitor the virological efficacy of antiretroviral treatment in resource poor countries. Lancet Infect Dis 2006; 6:53-59.
28. Lawn SD, Orrell C, Wood R. Evaluating a model for monitoring the virological efficacy of antiretroviral treatment in resource-limited settings. Lancet Infect Dis 2006; 6:385-386.
29. Smith-Rohrberg D, Basu S, Subbaraman R, Sharma SK. Compromising comprehensive AIDS management will lead to failure. Lancet Infect Dis 2006; 6:384-385.